Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation (I&I) indications, oncology, and genetic diseases. The company has developed QuEEN, a discovery engine, to enable its unique target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Monte Rosa Therapeutics ...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Monte Rosa Therapeutics (GLUE) and Curis (CRIS)

In a report released today, Brian Cheng from J.P. Morgan maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $30.00. Accordi...

J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Lantheus (LN...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $29.00. Accor...

Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alto Neuroscience, Inc. (ANRO – Research Report) and...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GLUE	$18.05	+5.43%	870.68K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GLUE	$18.05	+5.4%	870.68K
3
4
5
6

GLUE

GLUE

Dividend Overview

Get Monte Rosa Therapeutics Inc. Data in Excel

Get Monte Rosa Therapeutics Inc. Data in Excel